Leerink Partnrs Forecasts Penumbra’s Q3 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN) – Equities researchers at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for Penumbra in a report issued on Tuesday, February 18th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of $0.98 for the quarter, down from their previous forecast of $1.09. The consensus estimate for Penumbra’s current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for Penumbra’s Q4 2025 earnings at $1.11 EPS, FY2027 earnings at $6.86 EPS, FY2028 earnings at $7.92 EPS and FY2029 earnings at $8.96 EPS.

PEN has been the topic of several other research reports. BTIG Research raised their price objective on Penumbra from $232.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Royal Bank of Canada raised their price objective on Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a research note on Wednesday. Truist Financial lifted their target price on Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a research note on Wednesday. Robert W. Baird lifted their target price on Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, UBS Group lifted their target price on Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $292.64.

Penumbra Stock Down 3.5 %

PEN stock opened at $292.52 on Thursday. Penumbra has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The business’s 50-day moving average is $258.16 and its two-hundred day moving average is $227.04. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The company has a market cap of $11.27 billion, a price-to-earnings ratio of 860.35, a P/E/G ratio of 2.23 and a beta of 0.53.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million.

Hedge Funds Weigh In On Penumbra

A number of hedge funds have recently made changes to their positions in the company. True Wealth Design LLC purchased a new position in Penumbra in the third quarter worth approximately $26,000. UMB Bank n.a. boosted its position in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after buying an additional 70 shares during the period. Hurley Capital LLC purchased a new position in shares of Penumbra during the fourth quarter worth $56,000. Huntington National Bank boosted its position in shares of Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after buying an additional 154 shares during the period. Finally, Mather Group LLC. boosted its position in shares of Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after buying an additional 208 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Insider Activity at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 167 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the sale, the director now owns 8,530 shares in the company, valued at approximately $2,058,118.40. The trade was a 1.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Lambert Shiu sold 1,798 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $242.56, for a total value of $436,122.88. Following the sale, the chief accounting officer now owns 20,682 shares in the company, valued at approximately $5,016,625.92. The trade was a 8.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,219 shares of company stock valued at $4,426,439 in the last ninety days. Corporate insiders own 5.00% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.